A strong correlation was observed for all samples and samples with a confirmed diagnosis of lung cancer for all confirmed samples and samples (Figure 2A). The Bland-Altman analysis was performed to visualize the average difference in the percentage of tumor cells with the average PD-L1 expression of both trials (Figure 2B). The analysis revealed an average difference of 20 %, the PD-L1 IHC 22C3-Assay revealed the greatest coloring result of the membrane of tumor cells in 37 (82.8%). of the samples, while the PD-L1 IHC 28-8-dye test was most important in 8 (17.8%) samples. The dispersal of the trials for these patients did not reveal a motive, as it covered the space of expression. Statistical tests to assess the match between the trials included the Bland-Altman analysis; calculating the positive percentage agreement (EAA), the negative percentage agreement (APA) and the overall percentage agreement (OPA); And Cohen28 kappa statistics all statistical analyses were performed in R and validated in SAS (version 9.3). In this analysis, we found no significant difference in the percentage of positive PD-L1 tumor cells between trials. Despite a negligible decrease in the average frequency of coloration of tumor cells (-0.80% in all samples and -0.93% in the lungs) with the PD-L1 IHC 28-8 test, the two tests appear to be identical in all samples, and especially for lung cancer. Although there was no clear direction for platforms that detected a greater proportion of positive tumor cells of PD-L1, it was found that outliers were associated with >20% difference between platforms with high coloration, reported by 22C3. Pair comparison for lung cancer or unspecified cancer diagnosis for the most common biopsy sites (lungs or lymph nodes).
Bladder diagram of immuno-tinged adjusted tumor biopsies-28-8 and 22C3 against the chord line (orange). (A) diagnosis of lung cancer, lung biopsy point, No. 275. (B) unspecified cancer diagnosis, pulmonary biopsy point, No.804. (C) diagnosis of lung cancer, lymph node biopsy point, No.44. (D) unspecified diagnosis of cancer, lymph node biopsy point, No. 162. The size of the node is proportional to the number of observations with the same expression values 22C3 and 28-8. PD-L1, Scheduled Death League 1. To understand clinical effects, OPA, PPA, NPA and Cohen kappa were treated via PD-L1 expression levels (≥1%, ≥5%, ≥10%, ≥25% and ≥50%) calculated. These levels of expression are those used in clinical trials of anti-PD-1 and anti-PD-L1 agents.
The OPA was between 97% and 98% for all samples and between 95% and 98% for samples with a confirmed diagnosis of lung cancer across all expression thresholds (Table 2). Cohens Kappa coefficient, a statistic between 0 and 1 used to assess the match between category positions, was between 0.92 and 0.95 for all samples and 0.90 to 0.95 for lung cancer. Analysis of PD-L1 Tumor Membrane Coloring The match between PD-L1-Immunhistochemistry 22C3 and 28-8-Assays on all tumor biopsies or biopsies adapted with a confirmed diagnosis of lung cancer. (A) Bladder diagram of adjusted tumor biopsies tinged with immunehistochemistry PD-L1 28-8 and 22C3 against the identity line (orange). The size of the knot is proportional to the number of measurements. (B) Bland-Altman-Representation of the percentage difference in the membrane of colored tumor cells. The dotted lines represent the 2.5. and 97.5-percentiles for the difference between the two measured values; ineminent lines represent the average difference.